The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model
Chemotherapy · 2019 · 64 (5-6) · 224-232
DOI: 10.1159/000507540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 20.05.2020. Verfasst von Mao Hagihara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Aichi, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
With an increase in the incidence of Staphylococcus aureus infections in the healthcare settings and in the community, trimethoprim/sulfamethoxazole (TMP/SMX) has been suggested as a convenient treatment option. However, the appropriate dosage regimen of TMP/SMX is unclear.
Objective
This study aimed to examine the pharmacokinetics/pharmacodynamics (PK/PD) of TMP/SMX against S. aureus using a neutropenic murine thigh infection model.
Methods
Five S. aureus isolates with TMP/SMX (1:5 fixed ratio) minimum inhibitory concentrations (MICs) of 0.032–64 μg/mL were tested. The antimicrobial efficacy of TMP/SMX (1–689 mg/kg/day: dose shown as SMX dosage) was calculated as the change in bacterial density after 24 h of treatment. The plasma concentrations of TMP/SMX were detected using high-performance liquid chromatography.
Results
After TMP/SMX single dose (130 mg/kg), the half-life, area under the blood concentration curve (AUC0–∞), and the protein binding ratio of SMX were 1.5 h, 718.2 μg h/mL, and 73.0 ± 8.3%, respectively. The free AUC/MIC and free %time (%T) above the MIC of SMX were better correlated with the in vivo antimicrobial activity than Cmax/MIC (free AUC/MIC, R2 = 0.69; free %T > MIC, R2 = 0.71; free Cmax/MIC, R2 = 0.53). The distributed doses (2–3 times per day) of TMP/SMX (130, 260, and 390 mg/kg/day) showed higher antimicrobial activity than the single dosage. However, TMP/SMX did not show its antimicrobial activity at <100% free %T > MIC.
Conclusions
The TMP/SMX treatment demonstrated that the free AUC/MIC of SMX was the better predictor of the PK/PD index of TMP/SMX.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Aichi, Japan.
- Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
- Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan, mikamo@aichi-med-u.ac.jp.
Zitieren
APA
Hagihara, M., Kato, H., Uchida, S., Yamashita, R., Tanaka, S., Sakanashi, D., Shiota, A., Asai, N., Koizumi, Y., Suematsu, H., Yamagishi, Y., Namiki, N., & Mikamo, H. (2019). The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model. Chemotherapy, 64(5-6), 224-232. https://doi.org/10.1159/000507540
Vancouver
Hagihara M, Kato H, Uchida S, Yamashita R, Tanaka S, Sakanashi D, et al. The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model. Chemotherapy. 2019;64(5-6):224-232. doi:10.1159/000507540
BibTeX
@article{Hagihara2019,
author = {Hagihara, Mao and Kato, Hideo and Uchida, Shinya and Yamashita, Rieko and Tanaka, Shimako and Sakanashi, Daisuke and Shiota, Arufumi and Asai, Nobuhiro and Koizumi, Yusuke and Suematsu, Hiroyuki and Yamagishi, Yuka and Namiki, Noriyuki and Mikamo, Hiroshige},
title = {The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against Staphylococcus aureus with a Neutropenic Murine Thigh Infection Model},
journal = {Chemotherapy},
year = {2019},
volume = {64},
number = {5-6},
pages = {224--232},
doi = {10.1159/000507540}
}
EUVIMED